7 completed, 2 terminated, 1 withdrawn. 4 Phase 2, 3 Not applicable, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Not applicable | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
Follow Stage II Ovarian Epithelial Cancer: new trials by email Literature Review of Stage II Ovarian Epithelial Cancer trials Research Report on Stage II Ovarian Epithelial Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant management of therapy complications, musculoskeletal complications management/prevention - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Withdrawn | Roswell Park Cancer Institute | 2012-05-01 | 2012-07-09 | |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant ondansetron, survey administration, management of therapy complications - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 49 | 2008-08-08 | 2017-05-23 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant lithium carbonate, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Completed | Fred Hutchinson Cancer Center | 20 | 2006-06-01 | 2017-03-07 |
| AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer cediranib maleate - Fallopian Tube Cancer, Primary Peritoneal Serous Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2005-10-01 | 2015-11-09 |
| EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer EF5 - Primary Peritoneal Cavity Cancer, Stage I Endometrial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2005-02-01 | 2013-01-16 |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer adjuvant therapy, paclitaxel, carboplatin - Brenner Tumor, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 113 | 2004-06-01 | 2019-07-22 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer EF5, motexafin lutetium, pharmacological study - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix | Not applicable | Terminated | National Cancer Institute (NCI) | 30 | 2004-05-01 | 2013-01-16 |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) carboplatin, paclitaxel, docetaxel - Brenner Tumor, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2004-05-01 | 2019-07-22 |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer ipilimumab, therapeutic allogeneic lymphocytes - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2003-04-01 | 2013-03-27 |
Carcinoma, Ovarian Epithelial (10) · Breast Neoplasms (5) · Burkitt Lymphoma (5) · Congenital Abnormalities (5) · Hodgkin Disease (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Leukemia, Myeloid, Acute (5) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (5) · Lymphoma, Follicular (5) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Large-Cell, Immunoblastic (5) · Lymphoma, Mantle-Cell (5) · Lymphoma, Non-Hodgkin (5) · Neuroblastoma (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5)
Adnexal Diseases (10) · Carcinoma (10) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Genital Diseases (10) · Genital Diseases, Female (10) · Genital Neoplasms, Female (10) · Gonadal Disorders (10) · Neoplasms by Histologic Type (10) · Neoplasms by Site (10) · Neoplasms, Glandular and Epithelial (10) · Ovarian Diseases (10) · Ovarian Neoplasms (10)
Bevacizumab (2) · Carboplatin (2) · Paclitaxel (2) · Taxes (2) · CTLA-4 Antigen (1) · Chemotherapy, Adjuvant (1) · Deferasirox (1) · Docetaxel (1) · Ipilimumab (1) · Lithium (1) · Lithium Carbonate (1) · Ondansetron (1) · Therapeutics (1) · cediranib (1) · motexafin lutetium (1)
National Cancer Institute (NCI) (6) · Fred Hutchinson Cancer Center (2) · City of Hope Medical Center (1) · Roswell Park Cancer Institute (1)
United States (9) · Japan (1)
Christina Chu (1) · Ewa Carrier (1) · Joan Walker (1) · Leona Holmberg (1) · Mark Morgan (1) · Paul Martin (1) · Philip McCarthy (1) · Stephen Michael Hahn (1) · Ursula Matulonis (1) · Vinod Pullarkat, MD (1)
U10CA027469 (2), P01CA087971 (1), R01CA093891 (1), R21CA099346 (1), U01CA062490 (1)